Lisa  LaVange net worth and biography

Lisa LaVange Biography and Net Worth

Director of Simulations Plus

Dr. Lisa Lavange has been a director of the Company since May 1, 2019. Dr. LaVange graduated from the University of North Carolina (“UNC”) with a doctoral degree in Biostatistics. Dr. LaVange is currently Professor Emerita and former Chair of Biostatistics, retiring from UNC in October 2023. From 2011 to 2017, Dr. LaVange served as Director of the Office of Biostatistics in the Center for Drug Evaluation and Research (“CDER”) at the FDA, where she oversaw more than 200 statisticians involved in the review of new drugs, therapeutic biologics, and generics. She also established the FDA’s complex innovative design initiative and continues to contribute to research in innovative clinical trials design and analysis. Previously, she worked in the pharmaceutical industry at the level of Vice President. Dr. LaVange is a fellow of the American Statistical Association (“ASA”), was the 2018 ASA President, and served on the ASA Board of Directors from 2017 to 2019 (and as Chair in 2018). She is also a former Board member of the International Biometric Society and served as regional president. Dr. LaVange is the recipient of numerous awards in clinical, statistical, and regulatory science, including the 2020 award for Outstanding Contribution to Health in the Americas Region from the Drug Information Association and the 2023 ICH Award for Outstanding Contribution to Harmonization for Better Health, nominated by the US FDA.

What is Lisa LaVange's net worth?

The estimated net worth of Lisa LaVange is at least $229,300.30 as of May 14th, 2024. Dr. LaVange owns 7,373 shares of Simulations Plus stock worth more than $229,300 as of May 14th. This net worth evaluation does not reflect any other investments that Dr. LaVange may own. Learn More about Lisa LaVange's net worth.

How do I contact Lisa LaVange?

The corporate mailing address for Dr. LaVange and other Simulations Plus executives is 42505 10TH STREET WEST, LANCASTER CA, 93534. Simulations Plus can also be reached via phone at (661) 723-7723 and via email at investors@westerngas.com. Learn More on Lisa LaVange's contact information.

Has Lisa LaVange been buying or selling shares of Simulations Plus?

Lisa LaVange has not been actively trading shares of Simulations Plus within the last three months. Most recently, Lisa Lavange sold 500 shares of the business's stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $50.00, for a transaction totalling $25,000.00. Following the completion of the sale, the director now directly owns 7,373 shares of the company's stock, valued at $368,650. Learn More on Lisa LaVange's trading history.

Who are Simulations Plus' active insiders?

Simulations Plus' insider roster includes John DiBella, II (President, Physiologically Based Pharmacokinetics (PBPK), Cheminformatics), Anthony II (Insider), Lisa LaVange (Director), John Paglia (Director), Daniel Weiner (Director), and Walter Woltosz (Director). Learn More on Simulations Plus' active insiders.

Are insiders buying or selling shares of Simulations Plus?

In the last year, insiders at the technology company sold shares 11 times. They sold a total of 162,000 shares worth more than $5,678,045.00. The most recent insider tranaction occured on May, 1st when Director Walter S Woltosz sold 20,000 shares worth more than $670,200.00. Insiders at Simulations Plus own 19.4% of the company. Learn More about insider trades at Simulations Plus.

Information on this page was last updated on 5/1/2025.

Lisa LaVange Insider Trading History at Simulations Plus

See Full Table

Lisa LaVange Buying and Selling Activity at Simulations Plus

This chart shows Lisa Lavange's buying and selling at Simulations Plus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40k-$20k$0$20k$40kTotal Insider BuyingTotal Insider Selling

Simulations Plus Company Overview

Simulations Plus logo
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Read More

Today's Range

Now: $31.10
Low: $30.26
High: $31.24

50 Day Range

MA: $28.86
Low: $23.82
High: $35.88

2 Week Range

Now: $31.10
Low: $23.01
High: $51.22

Volume

229,173 shs

Average Volume

208,557 shs

Market Capitalization

$625.45 million

P/E Ratio

77.75

Dividend Yield

N/A

Beta

1.1